The Affymetrix GeneChip Scanner 3000,,, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
e across the image field because of misalignment. On any given scanner, the fluorescent intensity gradient can vary from edge to edge. The gradient may have opposite signs and/or unequal slopes. The implication of this characteristic is that a probeby- probe gain matching of two (or more) scanners is almost impossible. Gain calibration procedures can only match the average intensity of reference fluorescence material to an average target value. Even if the gain matching procedure was perfect, comparison of specific features from images of the same array scanned on different scanners can exhibit absolute intensity mismatches of 30% or more.
It should be noted that biological performance is not adversely affected, due to the Perfect Match/Mis-Match strategy (referred to as PM/MM) of the array design, coupled with robust Affymetrix Microarray Suite expression algorithms.
Affymetrix GeneChip Scanner 3000 System
FLYING OBJECTIVE LENS
The Affymetrix patented flying objective technology represents a radical departure from the previous GeneChip array scanner that employed pre-objective line-scan technology (Figure 2). Affymetrix patented Flying Objective Lens (FOL) technology addresses all of the above issues with a simple, yet elegant, opto-mechanical design. Scan speed is increased, optical distortion is decreased, and emission path alignment robustness is ensured by simultaneously moving the scanning mirrors and the objective lens. The scan motion, corresponding to the fast, or X-axis, is achieved by rotating a scan-arm (objective lens and mirror assembly) around a section of the optical path located between two mirrors, one fixed to the internal optics bench, the other in the center of the scan-arm. This optical structure creates a periscope, whose optical path is co-axial with the axis of rotation of the galvanometer, and carries both excitation (forward path) and emissionPage: All 1 2 3 4 5 6 7 8 9 10 Related biology technology :1
. Fine Tuning Your Data Analysis:
Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms2
. The New Affymetrix GeneChip Scanner 30003
. GeneChip Sample Cleanup Module for cleanup of cDNA and in vitro
. New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays5
. General Notes on Primer Design in PCR*6
. siRNA Design Guidelines7
. Avoid siRNA Design Altogether!8
. Cenix-Designed siRNAs for 95% of Human and Mouse Genomes9
. Designing a Successful qRT-PCR Experiment10
. Designing a Better siRNA11
. Designing Controls for siRNA
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ... Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... The Bio-Stack is compatible with BioTeks ... Speed, ease of use and walkaway ... microplate process. When used with the ... dispenser, the Bio-Stacks small footprint fits ...
... for the use of small interfering RNA ... the RNA interference,(RNAi) pathway have generated tremendous ... fields. siRNA for experimental use can be,synthesized ... then transfected into the target cells in ...
... scientists who have access to microarray scanning and ... with proteins from S&Ss antibody menu or from ... performed by the customer. Its as easy as ... with an expert and define the best adapted ...Biology Products: